Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab as first-line treatment for RAS/BRAF wild-type left-sided metastatic colorectal cancer
ChiCTR2100047220Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, capecitabine, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Jul 2021; status: recruiting.
02
Drugs
cetuximabcapecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100047220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047220.